Reuters
Dec 20 () - Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.
Agenus will get an upfront cash payment of $120 million and a $30 million equity investment, and will also be eligible to receive about $1.7 billion in potential future fees and milestones, the companies said in a statement on Thursday.
OCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
Dec 20 () - Gilead Sciences Inc has inked a collaboration agreement with Agenus Inc for the development and marketing of up to five novel immuno-oncology therapies.
Agenus will get an upfront cash payment of $120 million and a $30 million equity investment, and will also be eligible to receive about $1.7 billion in potential future fees and milestones, the companies said in a statement on Thursday.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
